MARKET

VERA

VERA

Vera Therapeutics, Inc.
NASDAQ
47.69
-0.84
-1.73%
After Hours: 48.00 +0.31 +0.65% 19:55 12/18 EST
OPEN
48.83
PREV CLOSE
48.53
HIGH
50.25
LOW
47.22
VOLUME
829.75K
TURNOVER
--
52 WEEK HIGH
51.19
52 WEEK LOW
18.53
MARKET CAP
3.34B
P/E (TTM)
-11.9683
1D
5D
1M
3M
1Y
5Y
1D
Evercore ISI Remains a Buy on Vera Therapeutics (VERA)
TipRanks · 11h ago
Vera Therapeutics Announces Departure of Chief Legal Officer
TipRanks · 14h ago
Vera Therapeutics Chief Legal Officer Jason Carter Departs
Reuters · 15h ago
Vera Therapeutics Chief Regulatory Officer William D. Turner Reports Sale of Common Shares
Reuters · 1d ago
50 heavily shorted laggards poised to rebound according to Wells Fargo
Seeking Alpha · 2d ago
Tuesday 12/16 Insider Buying Report: ASST, VERA
NASDAQ · 2d ago
Vera Therapeutics director buys $250K in common stock
TipRanks · 3d ago
Director Patrick G. Enright Reports Acquisition of Vera Therapeutics Common Shares
Reuters · 3d ago
More
About VERA
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.

Webull offers Vera Therapeutics Inc stock information, including NASDAQ: VERA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VERA stock methods without spending real money on the virtual paper trading platform.